The Experts below are selected from a list of 2280 Experts worldwide ranked by ideXlab platform
Ove Torring - One of the best experts on this subject based on the ideXlab platform.
-
birth defects after use of Antithyroid Drugs in early pregnancy a swedish nationwide study
European Journal of Endocrinology, 2017Co-Authors: Stine Linding Andersen, Stefan Lonn, Peter Vestergaard, Ove TorringAbstract:Objective Antithyroid Drugs (ATDs) may have teratogenic effects, but more evidence is needed on the risk and types of birth defects after the use of methimazole (MMI) and propylthiouracil (PTU). This study aimed to evaluate the association between the use of ATDs in early pregnancy and birth defects. Design Swedish nationwide register-based cohort study. Methods The study included 684 340 children live-born in Sweden from 2006 to 2012. Exposure groups defined by maternal ATD use in early pregnancy were MMI (n = 162); PTU (n = 218); MMI and PTU (n = 66); ATD before or after, but not in pregnancy (n = 1551) and non-exposed (never ATD (n = 682 343)). Outcome was cumulative incidence of birth defects diagnosed before two years of age. Results The cumulative incidence of birth defects was not significantly different in children exposed to MMI (6.8%, P = 0.6) or PTU (6.4%, P = 0.4) vs non-exposed (8.0%). For subtypes of birth defects, MMI was associated with an increased incidence of septal heart defects (P = 0.02). PTU was associated with ear (P = 0.005) and obstructive urinary system malformations (P = 0.006). A case of choanal atresia was observed after exposure to both MMI and PTU. The incidence of birth defects in children born to mothers who received ATD before or after, but not in pregnancy, was 8.8% and not significantly different from non-exposed (P = 0.3), MMI exposed (P = 0.4) or PTU exposed (P = 0.2). Conclusions MMI and PTU were associated with subtypes of birth defects previously reported, but the frequency of ATD exposure in early pregnancy was low and severe malformations described in the MMI embryopathy were rarely observed.
-
graves disease a long term quality of life follow up of patients randomized to treatment with Antithyroid Drugs radioiodine or surgery
Thyroid, 2005Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Leif Tallstedt, Ove Torring, Goran Lundell, Bertil Hamberger, Goran WallinAbstract:The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with Antithyroid Drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Jangustaf Ljunggren, Adam Taube, Maria Saaf, Bertil HambergerAbstract:Graves´ Hyperthyroidism: Treatment with Antithyroid Drugs, Surgery or Radioiodine - A prospective, Randomized Study
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Adam Taube, Maria Saaf, J G Ljunggren, Bertil HambergerAbstract:To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received Antithyroid Drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid Drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with Antithyroid Drugs are important factors to consider when selecting therapy for Graves' disease.
Bertil Hamberger - One of the best experts on this subject based on the ideXlab platform.
-
graves disease a long term quality of life follow up of patients randomized to treatment with Antithyroid Drugs radioiodine or surgery
Thyroid, 2005Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Leif Tallstedt, Ove Torring, Goran Lundell, Bertil Hamberger, Goran WallinAbstract:The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with Antithyroid Drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Jangustaf Ljunggren, Adam Taube, Maria Saaf, Bertil HambergerAbstract:Graves´ Hyperthyroidism: Treatment with Antithyroid Drugs, Surgery or Radioiodine - A prospective, Randomized Study
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Adam Taube, Maria Saaf, J G Ljunggren, Bertil HambergerAbstract:To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received Antithyroid Drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid Drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with Antithyroid Drugs are important factors to consider when selecting therapy for Graves' disease.
Goran Wallin - One of the best experts on this subject based on the ideXlab platform.
-
thyroid associated ophthalmopathy quality of life follow up of patients randomized to treatment with Antithyroid Drugs or radioiodine
European Journal of Endocrinology, 2010Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Bengt Hallengren, Pavo Hedner, Mikael Lantz, Frank Traisk, Gertrud Berg, Goran Wallin, Ernst Nystrom, Peter AsmanAbstract:Objective: The objective of this study was to investigate quality of life (QoL) in patients with Graves' disease treated with radioiodine or Antithyroid Drugs. Design and methods: The design of the study consists of an open, prospective, randomized multicenter trial between radioiodine and medical treatment. A total of 308 patients were included in the study group: 145 patients in the medical group and 163 patients in the radioiodine group. QoL was measured with a 36-item Short Form Health Status Survey questionnaire (SF-36) at six time points during the 48-month study period. Results: Patient who developed or got worse of thyroid-associated ophthalmopathy (TAO) at any time point during the 4-year study period (TAO group) had lower QoL when no respect was paid to the mode of treatment. TAO occurred in 75 patients who had radioiodine treatment at some time point during the study period as compared with TAO in 40 medically treated patients (P<0.0009). Comparisons between the group of patients who have had TAO versus the group without TAO, in relation to treatments and time, showed significantly decreased QoL scores for the TAO groups at several time points during the study. In patients without TAO, there were no differences in QoL related to mode of treatment. Conclusions: The QoL in patients with Graves' ophthalmopathy was similar in radioiodine and medically treated patients, but patients who developed or had worsening of TAO had decreased QoL independent of mode of treatment. Furthermore, patients with TAO recovered physically within 1 year but it took twice as long for them to recover mentally.
-
graves disease a long term quality of life follow up of patients randomized to treatment with Antithyroid Drugs radioiodine or surgery
Thyroid, 2005Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Leif Tallstedt, Ove Torring, Goran Lundell, Bertil Hamberger, Goran WallinAbstract:The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with Antithyroid Drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Jangustaf Ljunggren, Adam Taube, Maria Saaf, Bertil HambergerAbstract:Graves´ Hyperthyroidism: Treatment with Antithyroid Drugs, Surgery or Radioiodine - A prospective, Randomized Study
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Adam Taube, Maria Saaf, J G Ljunggren, Bertil HambergerAbstract:To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received Antithyroid Drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid Drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with Antithyroid Drugs are important factors to consider when selecting therapy for Graves' disease.
Leif Tallstedt - One of the best experts on this subject based on the ideXlab platform.
-
thyroid associated ophthalmopathy after treatment for graves hyperthyroidism with Antithyroid Drugs or iodine 131
The Journal of Clinical Endocrinology and Metabolism, 2009Co-Authors: Frank Traisk, Jan Calissendorff, Bengt Hallengren, Pavo Hedner, Mikael Lantz, Leif Tallstedt, Mirna Abrahamnordling, Gertrud Berg, Tommy Andersson, E NystromAbstract:Context: Previous randomized trials have suggested an association between radioiodine treatment for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy (TAO). Objectives: The aim of the study was to compare the occurrence of worsening or development of TAO in patients who were treated with radioiodine or Antithyroid Drugs. Design: We conducted a randomized trial (TT 96) with a follow-up of 4 yr. Patients, Setting, and Intervention: Patients with a recent diagnosis of Graves’ hyperthyroidism were randomized to treatment with iodine-131 (163 patients) or 18 months of medical treatment (150 patients). Early substitution with T4 was given in both groups. Main Outcome Measure: Worsening or development of TAO was significantly more common in the iodine-131 treatment group (63 patients; 38.7%) compared with the medical treatment group (32 patients; 21.3%) (P < 0.001). Results: The risk for de novo development of TAO was greater in patients treated with iodine-131 (53 patients) than with medical treatme...
-
graves disease a long term quality of life follow up of patients randomized to treatment with Antithyroid Drugs radioiodine or surgery
Thyroid, 2005Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Leif Tallstedt, Ove Torring, Goran Lundell, Bertil Hamberger, Goran WallinAbstract:The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with Antithyroid Drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Jangustaf Ljunggren, Adam Taube, Maria Saaf, Bertil HambergerAbstract:Graves´ Hyperthyroidism: Treatment with Antithyroid Drugs, Surgery or Radioiodine - A prospective, Randomized Study
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Adam Taube, Maria Saaf, J G Ljunggren, Bertil HambergerAbstract:To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received Antithyroid Drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid Drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with Antithyroid Drugs are important factors to consider when selecting therapy for Graves' disease.
Goran Lundell - One of the best experts on this subject based on the ideXlab platform.
-
graves disease a long term quality of life follow up of patients randomized to treatment with Antithyroid Drugs radioiodine or surgery
Thyroid, 2005Co-Authors: Mirna Abrahamnordling, Jan Calissendorff, Leif Tallstedt, Ove Torring, Goran Lundell, Bertil Hamberger, Goran WallinAbstract:The effects of treatment modality for Graves' disease (GD) were studied with respect to long-term quality of life and present health status. A total of 179 patients with GD were randomized during the period 1983-1990 for treatment with Antithyroid Drugs, radioiodine, or surgery. A 36-item Short Form Health Status Survey questionnaire and specific questions for GD were sent to patients 14-21 years after randomization. Present medical records, and clinical and laboratory status were recorded. No major significant differences in quality of life among the three treatments were observed. Compared to a large Swedish reference group, all treatment groups had significantly lower scores for vitality (p < 0.05). The Mental Component Summary was lower for both the young medical, young surgical, and the older medical group (p < 0.05). Radioiodine-treated patients had a lower General Health score. Young medical patients (<35 years) had lower Mental Health scores (p < 0.05). There was also a strong trend, which barely met statistically significance, for older surgical and radioiodine groups for lower Mental Component Summary. GD patients have, compared with a large Swedish reference population, diminished vital and mental quality of life aspects even many years after treatment. The quality-of-life scores were not different among the three treatment modalities.
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Jangustaf Ljunggren, Adam Taube, Maria Saaf, Bertil HambergerAbstract:Graves´ Hyperthyroidism: Treatment with Antithyroid Drugs, Surgery or Radioiodine - A prospective, Randomized Study
-
graves hyperthyroidism treatment with Antithyroid Drugs surgery or radioiodine a prospective randomized study thyroid study group
The Journal of Clinical Endocrinology and Metabolism, 1996Co-Authors: Ove Torring, Leif Tallstedt, Goran Wallin, Goran Lundell, Adam Taube, Maria Saaf, J G Ljunggren, Bertil HambergerAbstract:To analyze the benefits and risks of three common treatments, we randomly assigned 179 patients with Graves' hyperthyroidism as follows: 60 patients, 20-34 yr of age (young adults), received Antithyroid Drugs for 18 months (medical) or subtotal thyroidectomy (surgical), and 119 patients, 35-55 yr of age (old adults), received medical, surgical, or radioiodine (iodine-131) treatment. The follow-up time was at least 48 months. Antithyroid Drugs, surgery, or iodine-131 treatment normalized the mean serum hormone levels within 6 weeks. The risk of relapse was highest in the medically treated young and old adults (42% vs. 34%), followed by that in those treated with iodine-131 (21%) and that in the surgically treated young and old adults (3% vs 8%), respectively. Elevated TSH receptor antibodies at the end of medical therapy or increasing TSH receptor antibodies values after medical or surgical treatment increased the probability of relapse. Development or worsening of ophthalmopathy was not associated with relapse per se. Ninety percent of the subjects in all groups were satisfied with the treatment they received. No significant difference in sick-leave due to Graves' or other diseases was seen during the first 2 yr after initiation of therapy. The increased risk of ophthalmopathy in patients with high serum T3 levels, especially when treated with iodine-131, and the relatively high frequency of relapse after treatment with Antithyroid Drugs are important factors to consider when selecting therapy for Graves' disease.